Evidence map›Paper›PMID 35073912›Full record

ArticleRetrovirology2022

HIV-2/SIV Vpx antagonises NF-κB activation by targeting p65.

Douglas L Fink, James Cai, Matthew V X Whelan, Christopher Monit, Carlos Maluquer de Motes, Greg J Towers, Rebecca P Sumner

Open access · goldAbstract read
In one paragraph

Article in Retrovirology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Transcriptomic Analysis Reveals Key Pathways Influenced by HIV-2 Vpx.International journal of molecular sciences · 2025
    Article
  5. Article
  6. Review
  7. Review
  8. IFIH1 (MDA5) is required for innate immune detection of intron-containing RNA expressed from the HIV-1 provirus.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Douglas L FinkDivision of Infection and Immunity, University College London, 90 Gower Street, London, WC1E 6BT, UK.
James CaiDivision of Infection and Immunity, University College London, 90 Gower Street, London, WC1E 6BT, UK.
Matthew V X WhelanDivision of Infection and Immunity, University College London, 90 Gower Street, London, WC1E 6BT, UK.
Christopher MonitDivision of Infection and Immunity, University College London, 90 Gower Street, London, WC1E 6BT, UK.
Carlos Maluquer de MotesDepartment of Microbial Sciences, School of Biosciences and Medicine, University of Surrey, Guildford, UK.
Greg J Towers *Division of Infection and Immunity, University College London, 90 Gower Street, London, WC1E 6BT, UK.
Rebecca P Sumner *Division of Infection and Immunity, University College London, 90 Gower Street, London, WC1E 6BT, UK. rebecca.sumner@surrey.ac.uk.ORCID 0000-0003-0735-8649
University College London · GBUniversity of Surrey · GB

Funding

Biotechnology and Biological Sciences Research Council BB/T006501/1Medical Research Council G0801172Medical Research Council MR/S023380/1Wellcome Trust 214344
6 · The paper itself

Abstract

backgroundThe NF-κB family of transcription factors and associated signalling pathways are abundant and ubiquitous in human immune responses. Activation of NF-κB transcription factors by viral pathogen-associated molecular patterns, such as viral RNA and DNA, is fundamental to anti-viral innate immune defences and pro-inflammatory cytokine production that steers adaptive immune responses. Diverse non-viral stimuli, such as lipopolysaccharide and cytokines, also activate NF-κB and the same anti-pathogen gene networks. Viruses adapted to human cells often encode multiple proteins targeting the NF-κB pathway to mitigate the anti-viral effects of NF-κB-dependent host immunity.

resultsIn this study we have demonstrated using a variety of assays, in a number of different cell types including primary cells, that plasmid-encoded or virus-delivered simian immunodeficiency virus (SIV) accessory protein Vpx is a broad antagonist of NF-κB signalling active against diverse innate NF-κB agonists. Using targeted Vpx mutagenesis, we showed that this novel Vpx phenotype is independent of known Vpx cofactor DCAF1 and other cellular binding partners, including SAMHD1, STING and the HUSH complex. We found that Vpx co-immunoprecipitated with canonical NF-κB transcription factor p65, but not NF-κB family members p50 or p100, preventing nuclear translocation of p65. We found that broad antagonism of NF-κB activation by Vpx was conserved across distantly related lentiviruses as well as for Vpr from SIV Mona monkey (SIVmon), which has Vpx-like SAMHD1-degradation activity.

conclusionsWe have discovered a novel mechanism by which lentiviruses antagonise NF-κB activation by targeting p65. These findings extend our knowledge of how lentiviruses manipulate universal regulators of immunity to avoid the anti-viral sequelae of pro-inflammatory gene expression stimulated by both viral and extra-viral agonists. Importantly our findings are also relevant to the gene therapy field where virus-like particle associated Vpx is routinely used to enhance vector transduction through antagonism of SAMHD1, and perhaps also through manipulation of NF-κB.

Indexed as

HIV-2Simian Immunodeficiency VirusAnimalsNF-kappa BSAM Domain and HD Domain-Containing Protein 1Viral Regulatory and Accessory ProteinsNF-kappa BSAM Domain and HD Domain-Containing Protein 1Viral Regulatory and Accessory ProteinsHIV-2ImmunomodulatorNF-κBp65SIVVpx

Identifiers

PMID35073912
PMCPMC8785589
OpenAlexW4207005435

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.